Investor Relations

Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."

Stock Quote NVTR (Common Stock) $23.01 + 0.30 (1.32%)
Today's Open$23.00
Previous Close$22.71
Data as of 06/22/18 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $23.01 with a 52 week high of $23.66 and a 52 week low of $7.60.

Recent News

May 17, 2018

Nuvectra to Present at Two Upcoming Investor Conferences

PLANO, Texas, May 17, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at two upcoming investor conferences in June 2018.                   Event:   Jefferies 2018 Global Healthcare Conference  

Read More >

May 02, 2018

Nuvectra™ Reports First Quarter 2018 Financial Results

PLANO, Texas, May 02, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2018. Highlights Reported consolidated revenues of $10.6 million for the first quarter 2018, including total Algovita® sales of $9.1 million. Expanded U.S. commercial team. Completed follow-on public offering of common stock for gross proceeds of approximately $26.0 million in February

Read More >

Investor Contact

The Ruth Group
Brian Johnston
Tram Bui

There are currently no events scheduled.
Featured Presentations
Download Documentation Nuvectra Jefferies Presentation